doi: 10.3390/cancers3043838.
Targeted radionuclide therapy
Affiliations
- PMID: 24213114
- PMCID: PMC3763399
- DOI: 10.3390/cancers3043838
Item in Clipboard
Targeted radionuclide therapy
Cancers (Basel).
.
Abstract
Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. Several different radiopharmaceuticals are currently being used by various administration routes and targeting mechanisms. This article aims to briefly review the current status of targeted radiotherapy as well as to outline the advantages and disadvantages of radionuclides used for this purpose.
Similar articles
-
Targeted alpha therapy: part I.Curr Radiopharm. 2011 Jul;4(3):176. doi: 10.2174/1874471011104030176. Curr Radiopharm. 2011. PMID: 22201706
-
Clinical Advances and Perspectives in Targeted Radionuclide Therapy.Pharmaceutics. 2023 Jun 14;15(6):1733. doi: 10.3390/pharmaceutics15061733. Pharmaceutics. 2023. PMID: 37376181 Free PMC article. Review.
-
Radionuclide cancer therapy.Ann Nucl Med. 1998 Apr;12(2):61-70. doi: 10.1007/BF03164831. Ann Nucl Med. 1998. PMID: 9637275 Review.
-
A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?Pharmaceuticals (Basel). 2015 Jun 10;8(2):321-36. doi: 10.3390/ph8020321. Pharmaceuticals (Basel). 2015. PMID: 26066613 Free PMC article. Review.
-
Targeted radionuclide therapy--an overview.Curr Radiopharm. 2013 Sep;6(3):152-80. doi: 10.2174/18744710113066660023. Curr Radiopharm. 2013. PMID: 24059327 Review.
Cited by
-
An emerging interface between life science and nanotechnology: present status and prospects of reproductive healthcare aided by nano-biotechnology.Nano Rev. 2014 Feb 26;5. doi: 10.3402/nano.v5.22762. eCollection 2014. Nano Rev. 2014. PMID: 24600516 Free PMC article. Review.
-
A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.Theranostics. 2021 Jul 6;11(16):7911-7947. doi: 10.7150/thno.56639. eCollection 2021. Theranostics. 2021. PMID: 34335972 Free PMC article. Review.
-
HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models.Cancers (Basel). 2021 Jan 21;13(3):385. doi: 10.3390/cancers13030385. Cancers (Basel). 2021. PMID: 33494435 Free PMC article.
-
Radiopharmaceuticals and their applications in medicine.Signal Transduct Target Ther. 2025 Jan 3;10(1):1. doi: 10.1038/s41392-024-02041-6. Signal Transduct Target Ther. 2025. PMID: 39747850 Free PMC article. Review.
-
Combination of [177Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model.Pharmaceutics. 2022 Jun 16;14(6):1284. doi: 10.3390/pharmaceutics14061284. Pharmaceutics. 2022. PMID: 35745856 Free PMC article.
References
-
- Hajdu S.I. 2000 years of chemotherapy of tumors. Cancer. 2005;103:1097–1102. - PubMed
-
- DeVita V.T., Jr. Ann. Oncol.; The influence of information on drug resistance on protocol design: The Harry Kaplan Memorial Lecture given at the Fourth International Conference on Malignant Lymphoma; June 6–9, 1990; Lugano, Switzerland. 1991. pp. 93–106. - PubMed
-
- Volkert W.A., Goeckeler W.F., Ehrhardt G.J., Ketring A.R. Therapeutic radionuclides: Production and decay property considerations. J. Nucl. Med. 1991;32:174–185. - PubMed
-
- Hoefnagel C.A. Radionuclide cancer therapy. Ann. Nucl. Med. 1998;12:61–70. - PubMed
-
- Koppe M., Postema E., Aarts F., Oyen V.J.G., Bleichrodt R.P., Boerman O.J. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev. 2005;24:539–567. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
